Mounjaro, Suicidal Ideation and Mental Health: What Patients Should Know

Step 1: Understand why this concern was raised in the first place

The question of GLP-1 medicines and suicidal ideation first emerged in 2023, when the European Medicines Agency and the MHRA opened a review into semaglutide and liraglutide following a small number of spontaneous reports. That review concluded in early 2024: the agencies found no confirmed causal relationship, though they updated product information to ask prescribers and patients to remain alert to mood changes.

Tirzepatide (the active ingredient in Mounjaro) is a dual GIP and GLP-1 receptor agonist — a different mechanism to semaglutide alone. When regulators assessed the SURMOUNT clinical programme, which enrolled thousands of adults across its trials, psychiatric adverse events were tracked systematically. The SURMOUNT-1 data, published in the New England Journal of Medicine, did not identify a statistically significant excess of suicidal ideation or self-harm in the tirzepatide arms compared with placebo.

None of this makes the question irrelevant. Spontaneous post-marketing reports continue to feed into pharmacovigilance databases, and the Black Triangle (▼) status that Mounjaro holds in the UK means the MHRA is actively reviewing all incoming safety data. The honest answer is: no causal link has been found, and surveillance is ongoing. That is where the evidence sits right now.

Step 2: Know what the MHRA currently asks of prescribers and patients

A question our prescribers hear most weeks is whether Mounjaro is safe to take in someone who has a history of depression or anxiety. The MHRA's current position does not list a personal history of depression or anxiety as an absolute contraindication to tirzepatide. What the prescribing information does ask is that clinicians consider psychiatric history during assessment, and that patients are counselled to report any mood changes promptly.

The NHS patient information page for tirzepatide lists mood changes, depression, and thoughts of self-harm among the effects to tell a doctor about straight away, not because they are common, but because prompt reporting is the right response if they occur. You can read that list in full on the NHS tirzepatide medicines page. Separately, the MHRA's Yellow Card scheme at yellowcard.mhra.gov.uk is the mechanism through which patients themselves can file a report, and doing so genuinely shapes future regulatory decisions.

If you are currently taking Mounjaro and notice low mood, persistent hopelessness, or any thoughts of harming yourself, do not wait for your next scheduled review. Contact your prescriber the same day, call your GP, or call 999 or the Samaritans on 116 123 (free, 24 hours).

Step 3: Consider the broader mental health picture on a weight-loss medicine

Weight and mental health are closely connected, and that connection runs in both directions. Many people starting Mounjaro have lived with the psychological weight of obesity for years, low self-esteem, social withdrawal, and clinical depression are all more prevalent in people with higher BMIs. Starting treatment can lift some of that burden, but it can also surface emotions that were previously numbed by other coping patterns, including around food.

Appetite suppression on tirzepatide is significant. For some patients, the relationship with food changes quickly and dramatically. Eating less can feel disorienting. If food has been a primary source of comfort, that loss can trigger genuine low mood in the early weeks of treatment. This is not pharmacological suicidal ideation (it is a psychological adjustment) but it still matters, and it still warrants support. Letting your prescriber know is the right move, not something to push through alone.

Practical eating support during treatment makes a real difference here. Keeping meals structured and nutrient-dense even when appetite is low helps stabilise both energy and mood. For inspiration on what to put on your plate, our Mounjaro meal ideas guide offers a range of options that work well alongside treatment, and if you want structured daily eating suggestions to work from, our Mounjaro meal plan ideas page can help you build a practical routine around your appetite changes. If you are looking for ingredient-level inspiration, our page on Mounjaro food ideas breaks down which foods tend to sit well with tirzepatide. And for a broader look at structuring your eating day by day, we have put together a dedicated resource covering meal ideas while on Mounjaro that covers the practical side. More broadly, the Mounjaro treatment overview sets out what the full treatment journey looks like, including what clinical review involves.

Step 4: How ongoing monitoring works at a clinical level

Tirzepatide is a newer medicine and carries the Black Triangle designation precisely because the MHRA wants a fuller post-market picture before any monitoring requirements are relaxed. That designation is not a warning label (many medicines hold it at launch) but it does mean that safety information is evolving, and that every prescriber has a duty to review it regularly.

At nume, your consultation is read by a GPhC-registered Independent Prescriber before treatment is approved, not by an automated system. Psychiatric history is part of that assessment. Before each repeat order, a clinical review takes place again, there are no auto-renewals and no prescriptions issued without someone actually reading your record. If anything in your mental health has changed between orders, that review is the right place to raise it. You can also reach the team through our aftercare contact page at any time; support is available seven days a week.

For patients who want to understand how the wider cost and access picture fits together before starting, a plain-language breakdown is on the Mounjaro cost page. And if you are ready to discuss suitability with a prescriber directly, check your eligibility for a free consultation with our clinical team.